Castleark Management LLC Ultragenyx Pharmaceutical Inc. Transaction History

Castleark Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$62.2 - $84.4 $3 Million - $4.06 Million	-48,160 Closed	0 $0
Q4 2021 Feb 16, 2022	BUY	$73.71 - $87.86 $3.55 Million - $4.23 Million	48,160 New	48,160 $4.05 Million
Q1 2021 May 14, 2021	SELL	$106.9 - $167.73 $2.03 Million - $3.18 Million	-18,945 Closed	0 $0
Q4 2020 Feb 17, 2021	SELL	$84.4 - $177.39 $5.42 Million - $11.4 Million	-64,190 Reduced 77.21%	18,945 $2.62 Million
Q3 2020 Nov 16, 2020	SELL	$72.98 - $90.0 $15,690 - $19,350	-215 Reduced 0.26%	83,135 $6.83 Million
Q2 2020 Aug 14, 2020	SELL	$46.91 - $78.22 $39,873 - $66,487	-850 Reduced 1.01%	83,350 $6.52 Million
Q1 2020 May 13, 2020	BUY	$33.8 - $62.9 $2.85 Million - $5.3 Million	84,200 New	84,200 $3.74 Million
Q3 2019 Nov 15, 2019	SELL	$42.5 - $63.11 $2.42 Million - $3.6 Million	-56,995 Closed	0 $0
Q2 2019 Aug 13, 2019	SELL	$54.93 - $74.36 $10,436 - $14,128	-190 Reduced 0.33%	56,995 $3.62 Million
Q1 2019 May 14, 2019	BUY	$39.87 - $69.36 $2.28 Million - $3.97 Million	57,185 New	57,185 $3.97 Million

325

85.6M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $2.91B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Castleark Management LLC, based on Form 13F filings with the SEC.

Stay updated on Castleark Management LLC with notifications on news.